Detection of HIV-1 p24 Gag in plasma by a nanoparticle-based bio-barcode-amplification method

Nanomedicine

Volumn 3, Issue 3, 2008, Pages 293-303

  Kim, Eun Young ^a,b   Stanton, Jennifer ^a   Korber, Bette T M ^c   Krebs, Kendall ^a   Bogdan, Derek ^a   Kunstman, Kevin ^a   Wu, Samuel ^a   Phair, John P ^a   Mirkin, Chad A ^b   Wolinsky, Steven M ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

Bio barcode amplification method; HIV 1; Major core protein of HIV 1 (p24 Gag)

Indexed keywords

ANTIBODY; CD4 ANTIGEN; DNA; GAG PROTEIN; NANOPARTICLE; RECOMBINANT PROTEIN; VIRUS RNA;

ANTIBODY SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CLADISTICS; CONJUGATION; CONTROLLED STUDY; DNA BARCODING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE AMPLIFICATION; GENETIC CODE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAGNETISM; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN STRUCTURE; PROTEIN TARGETING; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL ASSAY; BLOOD CHEMICAL ANALYSIS; HIV CORE PROTEIN P24; HIV INFECTIONS; HUMANS; IMMUNOASSAY; IMMUNOMAGNETIC SEPARATION; NANOPARTICLES; NUCLEIC ACID AMPLIFICATION TECHNIQUES;

EID: 45149103759     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/17435889.3.3.293     Document Type: Article

References (38)

1. Mylonakis E, Paliou M, Lally M et al.: Laboratory testing for infection with the human immunodeficiency virus: established and novel approaches. Am. J. Med. 109, 568-576 (2000).
2. Burgisser P, Vernazza P, Flepp M et al.: Performance of five different assays for the quantification of viral load in persons infected with various subtypes of HIV-1. Swiss HIV Cohort Study. J. Acquir. Immune Defic. Syndr. 23, 138-144 (2000).
3. de Baar MP, Timmermans EC, Bakker M et al.: One-tube real-time isothermal amplification assay to identify and distinguish human immunodeficiency virus type 1 subtypes A, B, and C and circulating recombinant forms AE and AG. J. Clin. Microbial. 39, 1895-1902 (2001).
4. Lewin SR, Vesanen M, Kostrikis L et al.: Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1 -infected individuals on prolonged effective antiretroviral therapy. J. Virol. 73, 6099-6103 (1999).
5. Miles SA, Balden E, Magpantay L et al.: Rapid serologic testing with immune-complex-dissociated HIV p24 antigen for early detection of HIV infection in neonates. Southern California Pediatric AIDS Consortium. N Engl. J. Med. 328, 297-302 (1993).
6. Pascual A, Cachafeiro A, Funk ML et al.: Comparison of an assay using signal amplification of the heat-dissociated p24 antigen with the Roche Monitor human immunodeficiency virus RNA assay. J. Clin. Microbiol. 40, 2472-2475 (2002).
7. Rouet F, Ekouevi DK, Chaix ML et al.: Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J. Clin. Microbiol. 43, 2709-2717 (2005).
8. Sivapalasingam S, Essajee S, Nyambi PN et al.: Human immunodeficiency virus (HIV) reverse transcriptase activity correlates with HIV RNA load: implications for resource-limited settings. J. Clin. Microbiol. 43, 3793-3796 (2005).
9. Jennings C, Fiscus SA, Crowe SM et al.: Comparison of two human immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assay. J. Clin. Microbiol. 43, 5950-5956 (2005).
10. Pantaleo C, Fauci AS: Immunopathogenesis of HIV infection. Ann. Rev. Microbiol. 50, 825-854 (1996).
11. Lackritz EM, Satten GA, Aberle-Grasse J et al.: Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N. Engl. J. Med. 333, 1721-1725 (1995).
12. Bianco C et al.: U.S. Public Health Service guidelines for testing and counseling blood and plasma donors for human immunodeficiency virus type 1 antigen. MMWR Morb. Mortal. Wkly Rep. 45, 1-9 (1996).
13. Prado JG, Shintani A, Bofill M et al.: Lack of longitudinal intrapatient correlation between p24 antigenemia and levels of human immunodeficiency virus (HIV) type 1 RNA in patients with chronic HIV infection during structured treatment interruptions. J. Clin. Microbiol. 42, 1620-1625 (2004).
14. Sterling TR, Hoover DR. Astemborski J et al.: Heat-denatured human immunodeficiency virus type 1 protein 24 antigen: prognostic value in adults with early-stage disease. J. Infect. Dis. 186, 1181-1185 (2002).
15. Chadwick EG, Yogev R, Kwok S et al.: Enzymatic amplification of the human Immunodeficiency virus in peripheral blood mononuclear cells from pediatric patients. J. Infect. Dis. 160, 954-959 (1989).
16. Cunningham CK, Charbonneau TT, Song K et al..: Comparison of human immunodeficiency virus 1 DNA polymerase chain reaction and qualitative and quantitative RNA polymerase chain reaction in human immunodeficiency virus 1-exposed infants. Pediatr. Infect. Dis. J. 18, 30-35 (1999).
17. Nadal D, Böni J, Kind C et al.: Prospective evaluation of amplification-boosted ELISA for heat-denatured p24 antigen for diagnosis and monitoring of pediatric human immunodeficiency virus type 1 infection. J. Infect. Dis. 180, 1089-1095 (1999).
18. Respess RA, Cachafeiro A, Withum D et al.: Evaluation of an ultrasensitive p24 antigen assay as a potential alternative to human immunodeficiency virus type 1 RNA viral load assay in resource-limited settings. J. Clin. Microbiol. 43, 506-508 (2005).
19. Ribas SC, Ondoa P, Schüpbach J et al.: Performance of a quantitative human immunodeficiency virus type 1 p24 antigen assay on various HIV-1 subtypes for the follow-up of human immunodeficiency type 1 seropositive individuals. J. Virol. Methods 113, 29-34 (2003).
20. Schupbach J, Böni J, Flepp M et al.: Antiretroviral treatment monitoring with an improved HIV-1 p24 antigen test: an inexpensive alternative to tests for viral RNA. J. Med. Virol. 65, 225-232 (2001).
21. + T cell loss. J. Acquir. Immune Defic. Syndr. 40, 250-256 (2005).
22. Bao YP, Wei TF, Lefebvre PA et al.: Detection of protein analytes via nanoparticle-based bio bar code technology. Anal. Chem. 78, 2055-2059 (2006).
23. Nam JM, Thaxton CS, Mirkin CA: Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science 301, 1884-1886 (2003).
24. Shaikh KA, Ryu KS, Goluch ED et al. A modular microfluidic architecture for integrated biochemical analysis. Proc. Natl. Acad. Sci. USA 102, 9745-9750 (2005).
25. Tang S, Zhao J, Storhoff JJ et al.: Nanoparticle-based biobarcode amplification assay (BCA) for sensitive and early detection of human immunodeficiency type 1 capsid (p24) antigen. J. Acquir. Immune Defic. Syndr. 46, 231 (2007).
26. Taton TA, Mirkin CA, Letsinger RL: Scanometric DNA array detection with nanoparticle probes. Science 289, 1757-1760 (2000).
27. Gaschen B, Taylor J, Yusim K et al.: Diversity considerations in HIV-1 vaccine selection. Science 296, 2354-2360 (2002).
28. Kim EY, Stanton J, Vega RA et al.: A real-time PCR-based method for determining the surface coverage of thiolcapped oligonucleotides bound onto gold nanoparticles. Nucleic Acids Res. 34, e54 (2006).
29. Ledergerber B, Flepp M, Böni J et al.: Human immunodeficiency virus type 1 p24 concentration measured by boosted ELISA of heat-denatured plasma correlates with decline in CD4 cells, progression to AIDS, and survival: comparison with viral RNA measurement. J. Infect. Dis. 181, 1280-1288 (2000).
30. Ferns RB. Tedder RS, Weiss RA: Characterization of monoclonal antibodies against the human immunodeficiency virus (HIV) gag products and their use in monitoring HIV isolate variation. J. Geb. Virol. 68, 1543-1551 (1987).
31. Brown BK, Darden JM, Tovanabutra S et al.: Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01Æ, and CRF02_AG, for the development and assessment of candidate vaccines. J. Virol. 79, 6089-6101 (2005).
32. Bobrow MN, Harris TD, Shaughnessy KJ, Litt GJ: Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays. J. Immunol. Methods 125, 279-285 (1989).
33. Sano T, Smith CL, Cantor TR: Immuno-PCR: very sensitive antigen detection by means of specific antibody-DNA conjugates. Science 258, 120-122 (1992).
34. Tang S, Zhao J, Storhoff JJ et al.: Nanoparticle-based biobarcode amplification assay for sensitive and early detection of human immunodeficiency type 1 capsid antigen. J. Acquir. Immune Defic. Syndr. 46, 231-237 (2007).
35. Briggs JA, Simon MN, Gross I et al.: The stoichiometry of Gag protein in HIV-1. Nat. Struct. Mol. Biol. 11, 672-675 (2004).
36. Furtado MR, Callaway DS, Phair JP et al.: Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N. Engl. J. Med. 340, 1614-1622 (1999).
37. Kaplan AH, Zack JA, Knigge M et al..: Partial inhibition of the human immunodeficiency virus type-1 protease results in aberrant virus assembly and the formation of noninfectious particles. J. Virol. 67, 4050-4055 (1993).
38. Wang SW, Aldovini A: RNA incorporation is critical for retroviral particle integrity after cell membrane assembly of Gag complexes. J. Virol. 76, 11853-11865 (2002).